TD Cowen Reiterates Buy Rating on Astria Therapeutics (ATXS)

November 20, 2024 7:39 AM EST Send to a Friend
TD Cowen analyst Stacy Ku reiterated a Buy rating and $35.00 price target on Astria Therapeutics (NASDAQ: ATXS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login